SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPGNewsfile Corp • 03/15/21
GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIESGlobeNewsWire • 03/04/21
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/20/21
The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley BullishBenzinga • 01/19/21
Galapagos' CEO makes donation of €10 million in the form of personal shares to African ParksGlobeNewsWire • 12/23/20
Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls ApartInvestors Business Daily • 12/16/20
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) GlobeNewsWire • 12/15/20
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)Business Wire • 12/15/20
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney diseaseGlobeNewsWire • 12/01/20
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial GlobeNewsWire • 11/30/20